Host endosomal entry / trafficking
MoreNasal & Oral Sprays / Rinses
MoreHost targets and pathways
MoreInflammatory and immune modulation
MoreOxidative stress and cytoprotection
MoreReplication inhibition (target unresolved)
MorePleiotropic modulation
MoreAttachment / entry inhibition
MoreNutrients and microbiome support
MoreIL-6 / IL-6R blockade
MorePhysical and extracorporeal interventions
MoreNatural products and extracts
MoreUnconfirmed antiviral rationale
MoreLifestyle, behaviors, and exposure prevention
MoreOther complication management
MoreHost pyrimidine synthesis
MoreDirect viral inactivation
MoreEndothelial / vascular protection
MoreDirect respiratory tract treatments
MoreOther antibodies, proteins, peptides, cells, and RNA therapies
MoreSecondary infection and coinfection management
More
124 patient antroquinonol late treatment RCT: 200% higher progression (p=1), 17% slower recovery (p=0.72), 2% shorter hospitalization (p=0.92), and 7% faster viral clearance (p=0.87).
RCT 124 hospitalized COVID-19 patients showing no significant differences with antroquinonol.
Dec 2021, NCT04523181, https://clinicaltrials.gov/study/NCT04523181, https://c19p.org/cheng7